Roman Willi

Statistics

Publications

Citations

1.7K

H-Index

Active since

1989

Affiliations

Novartis (United States)(Current)

Novartis (Switzerland)

ETH Zurich

Heinrich Heine University Düsseldorf

Washington University in St. Louis

Roman Willi is an author at Novartis (United States) specializing in life sciences, multiple sclerosis therapy, and relapsing-remitting multiple sclerosis treatment.

ORCID

Publications per year

1989–2022

Publications

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Stephen L. Hauser, Amit Bar‐Or, Jeffrey Cohen et al. · New England Journal of Medicine · 2020 · 700 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Stress in Puberty Unmasks Latent Neuropathological Consequences of Prenatal Immune Activation in Mice

Sandra Giovanoli, Harald Engler, Andrea Engler et al. · Science · 2013 · 464 citations · Full text

Medicine, Neurobiology, Psychiatry +17

Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II

Jutta Gärtner, Stephen L. Hauser, Amit Bar‐Or et al. · Multiple Sclerosis Journal · 2022 · 101 citations · Full text

Medicine, Neurology, Pharmacotherapy +14

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years

Stephen L. Hauser, Anne H. Cross, Kevin Winthrop et al. · Multiple Sclerosis Journal · 2022 · 78 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +17

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study

Amit Bar‐Or, Heinz Wiendl, Xavier Montalbán et al. · Multiple Sclerosis Journal · 2021 · 62 citations · Full text

Life Sciences, Immunology, Pharmacology +17

1–5 of 15